224 related articles for article (PubMed ID: 34922087)
1. HDAC inhibitors: Targets for tumor therapy, immune modulation and lung diseases.
Shanmugam G; Rakshit S; Sarkar K
Transl Oncol; 2022 Feb; 16():101312. PubMed ID: 34922087
[TBL] [Abstract][Full Text] [Related]
2. HDAC inhibition regulates oxidative stress in CD4
Shanmugam G; Subramaniyam K; George M; Sarkar K
Int Immunopharmacol; 2023 Sep; 122():110661. PubMed ID: 37473712
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylases as targets in autoimmune and autoinflammatory diseases.
Hamminger P; Rica R; Ellmeier W
Adv Immunol; 2020; 147():1-59. PubMed ID: 32981634
[TBL] [Abstract][Full Text] [Related]
4. [Epigenetic mechanisms and alcohol use disorders: a potential therapeutic target].
Legastelois R; Jeanblanc J; Vilpoux C; Bourguet E; Naassila M
Biol Aujourdhui; 2017; 211(1):83-91. PubMed ID: 28682229
[TBL] [Abstract][Full Text] [Related]
5. Progress in discovery and development of natural inhibitors of histone deacetylases (HDACs) as anti-cancer agents.
Wahi A; Jain P; Sinhari A; Jadhav HR
Naunyn Schmiedebergs Arch Pharmacol; 2024 Feb; 397(2):675-702. PubMed ID: 37615708
[TBL] [Abstract][Full Text] [Related]
6. Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs).
Luo Y; Li H
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33266366
[TBL] [Abstract][Full Text] [Related]
7. Current trends in development of HDAC-based chemotherapeutics.
Cheshmazar N; Hamzeh-Mivehroud M; Nozad Charoudeh H; Hemmati S; Melesina J; Dastmalchi S
Life Sci; 2022 Nov; 308():120946. PubMed ID: 36096240
[TBL] [Abstract][Full Text] [Related]
8. Role of histone deacetylases and their inhibitors in cancer biology and treatment.
Beumer JH; Tawbi H
Curr Clin Pharmacol; 2010 Aug; 5(3):196-208. PubMed ID: 20406169
[TBL] [Abstract][Full Text] [Related]
9. HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases.
Yoon S; Eom GH
Chonnam Med J; 2016 Jan; 52(1):1-11. PubMed ID: 26865995
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylases modulate resistance to the therapy in lung cancer.
Contreras-Sanzón E; Prado-Garcia H; Romero-Garcia S; Nuñez-Corona D; Ortiz-Quintero B; Luna-Rivero C; Martínez-Cruz V; Carlos-Reyes Á
Front Genet; 2022; 13():960263. PubMed ID: 36263432
[TBL] [Abstract][Full Text] [Related]
11. Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option.
Korfei M; Mahavadi P; Guenther A
Cells; 2022 May; 11(10):. PubMed ID: 35626663
[TBL] [Abstract][Full Text] [Related]
12. Recent Advances in Computer-Assisted Structure-Based Identification and Design of Histone Deacetylases Inhibitors.
Krishna S; Kumar V; Siddiqi MI
Curr Top Med Chem; 2016; 16(9):934-47. PubMed ID: 26303428
[TBL] [Abstract][Full Text] [Related]
13. Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide.
Chang J; Varghese DS; Gillam MC; Peyton M; Modi B; Schiltz RL; Girard L; Martinez ED
Br J Cancer; 2012 Jan; 106(1):116-25. PubMed ID: 22158273
[TBL] [Abstract][Full Text] [Related]
14. Plant Isoquinoline Alkaloid Berberine Exhibits Chromatin Remodeling by Modulation of Histone Deacetylase To Induce Growth Arrest and Apoptosis in the A549 Cell Line.
Kalaiarasi A; Anusha C; Sankar R; Rajasekaran S; John Marshal J; Muthusamy K; Ravikumar V
J Agric Food Chem; 2016 Dec; 64(50):9542-9550. PubMed ID: 27936791
[TBL] [Abstract][Full Text] [Related]
15. Novel Approaches Towards Designing of Isoform-Selective Inhibitors Against Class II Histone Deacetylases: The Acute Requirement for Targetted Anticancer Therapy.
Ganai SA
Curr Top Med Chem; 2016; 16(22):2441-52. PubMed ID: 26873193
[TBL] [Abstract][Full Text] [Related]
16. Review article: selective histone deacetylase isoforms as potential therapeutic targets in inflammatory bowel diseases.
Felice C; Lewis A; Armuzzi A; Lindsay JO; Silver A
Aliment Pharmacol Ther; 2015 Jan; 41(1):26-38. PubMed ID: 25367825
[TBL] [Abstract][Full Text] [Related]
17. HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis.
Lyu X; Hu M; Peng J; Zhang X; Sanders YY
Ther Adv Chronic Dis; 2019; 10():2040622319862697. PubMed ID: 31367296
[TBL] [Abstract][Full Text] [Related]
18. HDAC 3-selective inhibitor RGFP966 demonstrates anti-inflammatory properties in RAW 264.7 macrophages and mouse precision-cut lung slices by attenuating NF-κB p65 transcriptional activity.
Leus NG; van der Wouden PE; van den Bosch T; Hooghiemstra WTR; Ourailidou ME; Kistemaker LE; Bischoff R; Gosens R; Haisma HJ; Dekker FJ
Biochem Pharmacol; 2016 May; 108():58-74. PubMed ID: 26993378
[TBL] [Abstract][Full Text] [Related]
19. Anticancer activities of histone deacetylase inhibitors.
Bolden JE; Peart MJ; Johnstone RW
Nat Rev Drug Discov; 2006 Sep; 5(9):769-84. PubMed ID: 16955068
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylases function as novel potential therapeutic targets for cancer.
Zhang H; Shang YP; Chen HY; Li J
Hepatol Res; 2017 Feb; 47(2):149-159. PubMed ID: 27457249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
